Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anaprazole + rabeprazole
- Development stage
- Unknown
- Lead developer
- Shandong Luoxin Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Anaprazole + rabeprazole is a hypothetical combination of **two proton pump inhibitors (PPIs)**: anaprazole, a novel PPI investigated for peptic ulcer disease, and rabeprazole, a widely used and FDA-approved PPI for various acid-related gastrointestinal disorders. Both drugs act to decrease gastric acid secretion by inhibiting the gastric H^+/K^+-ATPase in the parietal cells of the stomach. Anaprazole has demonstrated non-inferiority to rabeprazole for the healing of duodenal ulcers in clinical studies[5]. Rabeprazole is used to treat peptic ulcers, gastroesophageal reflux disease (GERD), and conditions of excessive stomach acid, such as Zollinger-Ellison syndrome. There is no evidence from the search results or the current medical literature that anaprazole and rabeprazole are co-formulated or co-administered as a fixed combination product in clinical practice.
- Brand names
- Aciphex (rabeprazole)
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on anaprazole + rabeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anaprazole + rabeprazole.